Alzheimer's, Elan | featured news

J&J to Take Stake in Elan

J&J to Take Stake in Elan

J&J agreed to buy an 18.4% stake in Elan for $1 billion and acquire the rights to much of the Irish biotech company's research into drugs for Alzheimer's disease.

 

Subscribe to this RSS topic: Syndicate content